Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Jan 14:8:21-33.
doi: 10.2147/NSS.S76706. eCollection 2016.

Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies

Elena Urrestarazu  1 , Jorge Iriarte  1
Affiliations
Review

Clinical management of sleep disturbances in Alzheimer's disease: current and emerging strategies

Elena Urrestarazu et al. Nat Sci Sleep. .

Abstract

Sleep and circadian disorders in Alzheimer's disease (AD) are more frequent than in the general population and appear early in the course of the disease. Quality of sleep and quality of life are parallel in these patients, and such disorders also represent a heavy burden for caregivers. Although alterations in melatonin and hypocretins (orexins) seem to play a key role in the origin of these disturbances, the etiology of these disorders is multifactorial, including many factors such as environment, behavior, treatments, and comorbidities, among others. A comprehensive evaluation of sleep in each patient is essential in the design of the treatment that includes nonpharmacological and pharmacological approaches. One particularly interesting point is the possibility of a role of sleep disorders in the pathogenesis of AD, raising the possibility that treating the sleep disorder may alter the course of the disease. In this review, we present an update on the role of sleep disorders in AD, the bidirectional influence of sleep problems and AD, and treatment options. Behavioral measures, bright light therapy (BLT), melatonin, and other drugs are likely well known and correctly managed by the physicians in charge of these patients. In spite of the multiple treatments used, evidence of efficacy is scarce and more randomized double-blind placebo-controlled studies are needed. Future directions for treatment are the establishment of BLT protocols and the development of drugs with new mechanisms of action, especially hypocretin receptor antagonists, melatonin receptor agonists, and molecules that modulate the circadian clock.

Keywords: Alzheimer disease; circadian rhythm; melatonin; sleep disorders.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Bidirectional relationship between sleep and AD pathology. Abbreviations: SCN, suprachiasmatic nucleus; AD, Alzheimer’s disease.
Figure 2
Figure 2
Diagram with the clinical evaluation of the sleep disorders in AD patients. Abbreviations: AD, Alzheimer’s disease; PSG, polysomnography.
See this image and copyright information in PMC

References

    1. Hebert LE, Weuve J, Scherr PA, Evans DA. Alzheimer disease in the United States (2010–2050) estimated using the 2010 census. Neurology. 2013;80(19):1778–1783. - PMC - PubMed
    1. Pistacchi M, Gioulis M, Contin F, Sanson F, Marsala SZ. Sleep disturbance and cognitive disorder: epidemiological analysis in a cohort of 263 patients. Neurol Sci. 2014;35(12):1955–1962. - PubMed
    1. Moran M, Lynch CA, Walsh C, Coen R, Coakley D, Lawlor BA. Sleep disturbance in mild to moderate Alzheimer’s disease. Sleep Med. 2005;6(4):347–352. - PubMed
    1. Cipriani G, Lucetti C, Danti S, Nuti A. Sleep disturbances and dementia. Psychogeriatrics. 2015;15(1):65–74. - PubMed
    1. Vitiello MV, Borson S. Sleep disturbances in patients with Alzheimer’s disease: epidemiology, pathophysiology and treatment. CNS Drugs. 2001;15(10):777–796. - PubMed

LinkOut - more resources